Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Risk of metformin use in patients with T2DM and advanced CKD

Nature Reviews Endocrinology volume 11, pages 697–699 (2015)Cite this article

Subjects

In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schernthaner, G. & Schernthaner, G. H. In Pharmacotherapy of Diabetes: New Developments (ed. Mogensen, C. E.) 77–86 (Springer, 2007).

    Book  Google Scholar 

  2. Hung, S.-C. et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 3, 605–614 (2015).

    Article  CAS  Google Scholar 

  3. Chowdhury, T. A., Wright, R. & Yaqoob, M. M. Using metformin in the presence of renal disease. BMJ http://dx.doi.org/10.1136/bmj.h1758.

  4. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J. & McGuire, D. K. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312, 2668–2675 (2014).

    Article  Google Scholar 

  5. Roussel, R. et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 170, 1892–1899 (2010).

    Article  CAS  Google Scholar 

  6. Ekström, N. et al. Effectiveness and safety of metformin in 51,675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2, e001076 (2012).

    Article  Google Scholar 

  7. Lalau, J. D., Arnouts, P., Sharif, A. & De Broe, M. E. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 87, 308–322 (2015).

    Article  CAS  Google Scholar 

  8. Stanton, R. C. Metformin use in type 2 diabetes mellitus with CKD: is it time to liberalize dosing recommendations? Am. J. Kidney Dis. 66, 193–195 (2015).

    Article  CAS  Google Scholar 

  9. Penfornis, A., Blicklé, J. F., Fiquet, B., Quéré, S. & Dejager, S. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc. Health Risk Manag. 10, 341–352 (2014).

    PubMed  PubMed Central  Google Scholar 

  10. Duong, J. K. et al. The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf. 36, 733–746 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine 1, Rudolfstiftung Hospital, Juchgasse 25, Vienna, 1030, Austria

    Guntram Schernthaner

  2. Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18–20, Vienna, 1090, Austria

    Marie Helene Schernthaner-Reiter

Authors
  1. Guntram Schernthaner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Helene Schernthaner-Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guntram Schernthaner.

Ethics declarations

Competing interests

G.S. has served on advisory boards for Astra Zeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Eli Lilly, Johnston & Johnston and Takeda, and has served as a speaker for Astra Zeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Sanofi and Takeda. M.H.S.-R. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schernthaner, G., Schernthaner-Reiter, M. Risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 11, 697–699 (2015). https://doi.org/10.1038/nrendo.2015.132

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2015.132

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing